Enzymatic treatment of retinitis pigmentosa and relevant pharmaceutical composition therefor in form of a kit
OwnerPaola Ammannati, Roberto Giordaniinventors
Life of this patent
Estimating the term…
Abstract
A kit for the treatment of retinitis pigmentosa containing the enzymes glutathione peroxidase, prolidase, glucose-6-phosphate dehydrogenase and, optionally, aldose reductase in aliquot parts and interactive quantities appropriate for administering said enzymes in accordance with a predefined time sequence.
Claims9
A pharmaceutical kit for treatment of retinitis pigmentos is containing the enzymes glutathione peroxidase (Enzyme A), prolidase (Enzyme B), glucose-6-phosphate dehydrogenase (Enzyme C) and, optionally, aldose reductase (Enzyme D) in aliquot parts and interactive quantities appropriate for administering:
- a) Enzyme A at a concentration generally within a range of 0.03 and 0.05 U.I. in about 0.4 ml of physiological solution for approximately three consecutive days, at monthly intervals, for about three months and for each eye;
- b) Enzyme B, starting from the month following the last administration of Enzyme A, at a concentration generally within a range of 5 and 7 U.I. in about 0.4 ml of physiological solution for approximately three consecutive days, at monthly intervals, for about three months and for each eye;
- c) Enzyme C, starting from the month following the last administration of Enzyme B, at a concentration generally within a range of 7 and 9 U.I. in about 0.4 ml of physiological solution for approximately three consecutive days, at monthly intervals, for about three months and for each eye.
- d) Enzyme D, starting from the month following the last administration of Enzyme C, at a concentration generally within a range of 5 and 7 U.I. in about 0.4 ml of physiological solution for approximately three consecutive days, at monthly intervals, for about three months and for each eye.
Use of the enzymes glutathione peroxidase (Enzyme A), prolidase (Enzyme B), glucose-6-phosphate dehydrogenase (Enzyme C) and, optionally, aldose reductase (Enzyme D) for the preparation of a pharmaceutical composition in kit form for treatment of retinitis pigmentos is by injection into the retrobulbar tissue, the kit containing the enzymes in aliquot parts and interactive quantities appropriate for administering:
- a) Enzyme A at a concentration generally within a range of 0.03 and 0.05 U.I. in about 0.4 ml of physiological solution for approximately three consecutive days, at monthly intervals, for about three months and for each eye;
- b) Enzyme B, starting from the month following the last administration of Enzyme A, at a concentration generally within a range of 5 and 7 U.I. in about 0.4 ml of physiological solution for approximately three consecutive days, at monthly intervals, for about three months and for each eye;
- c) Enzyme C, starting from the month following the last administration of Enzyme B, at a concentration generally within a range of 7 and 9 U.I. in about 0.4 ml of physiological solution for approximately three consecutive days, at monthly intervals, for about three months and for each eye.
- d) Enzyme D, starting from the month following the last administration of Enzyme C, at a concentration generally within a range of 5 and 7 U.I. in about 0.4 ml of physiological solution for approximately three consecutive days, at monthly intervals, for about three months and for each eye.
A method for treatment of retinitis pigmentos is that envisages the administration by injection into the retrobulbar tissue of:
- a) Enzyme A at a concentration generally within a range of 0.03 and 0.05 U.I. in about 0.4 ml of physiological solution for approximately three consecutive days, at monthly intervals, for about three months and for each eye;
- b) Enzyme B, starting from the month following the last administration of Enzyme A, at a concentration generally within a range of 5 and 7 U.I. in about 0.4 ml of physiological solution for approximately three consecutive days, at monthly intervals, for about three months and for each eye;
- c) Enzyme C, starting from the month following the last administration of Enzyme B, at a concentration generally within a range of 7 and 9 U.I. in about 0.4 ml of physiological solution for approximately three consecutive days, at monthly intervals, for about three months and for each eye;
Dependencies are inferred from the claim text.